Company profile
Eli Lilly and Company logo

Eli Lilly and Company

Pipeline10 assets

Latest news25 items

All news

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapy New analyses of the ATTAIN program highlight Foundayo' s profile in

Presentation / Abstract • Phase 3Retatrutide symposium Sat, Jun 6, 2026, 1:30 PM CDT

Foundayo and Zepbound now covered for millions of Americans

CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicine INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all three of

Lilly announces three acquisitions to build infectious disease portfolio

Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease VERVE-102 is designed to mimic the protective

Interim Data • Phase 1Interim data Fri, Feb 27, 2026

Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight of up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2

INDIANAPOLIS, May 22, 2026 – Eli Lilly and Company (NYSE: LLY) announced a new analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials showing that Foundayo (orforglipron), was associated with clinically significant body weight reductions in adults aged 65 and

Presentation / Abstract • Phase 3ECO 2026 poster presentation Tue, May 12, 2026

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study of Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma also selected for

Presentation / Abstract • Phase 3ASCO press program Sat, May 30, 2026, CDT

Lilly and UNICEF collaborate to give millions of children a healthier start

Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries NEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one year In ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, participants who switched from Zepbound

Trial Results • Phase 3ECO presentation and publication Tue, May 12, 2026

Lilly declares second-quarter 2026 dividend

INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on June 10, 2026, to shareholders of record at the close of business

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs.

Trial Results • Phase 3

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm This trial predominantly enrolled a patient population previously treated with covalent BTK inhibitors, highly relevant to current practice These results mark the fourth positive Phase 3

Trial Results • Phase 3
Eli Lilly and Company • Endpoint Arena